OTC · Healthcare
CYANOTECH CORP (CYAN)
As-reported financials and recent SEC filings for CYANOTECH CORP, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$24.2M
Net income
$-3.2M
Net margin
-13.2%
Diluted EPS
—
ROE
-36.1%
P/E (TTM)
—
Market cap
—
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $24.2M | $23.1M | $23.2M | $36.0M | $32.3M |
| Gross profit | $6.9M | $5.9M | $7.3M | $13.6M | $11.1M |
| Operating income | $-2.5M | $-4.6M | $-2.9M | $2.6M | $84,000 |
| Net income | $-3.2M | $-5.3M | $-3.4M | $2.2M | $920,000 |
| Diluted EPS | — | $-0.81 | $-0.00 | $0.00 | $0.14 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
15-12G2026-02-13
View on EDGAR →SC 13E3/A2026-02-13
View on EDGAR →SC 13E3/A2026-02-03
View on EDGAR →SC 13E32026-01-09
View on EDGAR →10-Q2025-11-10
View on EDGAR →42025-09-16
View on EDGAR →32025-09-12
View on EDGAR →42025-09-02
View on EDGAR →Largest Healthcare peers
Go deeper on CYAN
Search CYANOTECH CORP’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.